{"title":"A case of adverse skin reactions to coronavirus disease 2019 vaccine successfully treated with eppikajutsuto","authors":"Koumei Kameyama, H. Nakae, Yasuhito Irie","doi":"10.46459/pmu.2021006","DOIUrl":"https://doi.org/10.46459/pmu.2021006","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"73 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76578138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Yamashita, Mao Takayama, T. So, H. Shimokawa, Masatoshi Yamaoka, T. Yoshimatsu, T. Oyama, A. Gotoh
{"title":"Airway stenting using Ultraflex for central airway stenosis due to lung cancer: A case report","authors":"N. Yamashita, Mao Takayama, T. So, H. Shimokawa, Masatoshi Yamaoka, T. Yoshimatsu, T. Oyama, A. Gotoh","doi":"10.46459/pmu.2022001","DOIUrl":"https://doi.org/10.46459/pmu.2022001","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87618906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of regenerative invariant NKT cells in cancer immunotherapy for head and neck cancer","authors":"S. Motohashi","doi":"10.46459/pmu.2022004","DOIUrl":"https://doi.org/10.46459/pmu.2022004","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88489144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
: Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are two major causes of dementia. These diseases are both progressive neurodegenerative diseases whereas no curative treatment has not yet been established. Regenerative approaches have been extensively researched for AD and FTD, but they are still in early phase of pre-clinical trials. We show here, for the first time, that cytokines such as hepatocyte growth factor (HGF), granulocyte colony stimulating factor (GCSF), insulin-like growth factors (IGFs), and progranulin (PGRN) can induce the neurogenesis of GABAergic and glutamatergic neurons in cerebral cortex and hippocampi of AD and FTD patients. We also showed the evidence, for the first time, that the atrophied hippocampi were significantly regenerated by cytokine-induced neurogenesis in AD and FTD patients, which was confirmed by MRI study and neurophysiological evaluations. We therefore explored the potentiality of cytokine cocktail treatment for AD and FTD and showed that cytokine-induced neurogenesis is a novel promising strategy to cure AD and FTD.
{"title":"Cytokine-induced Neurogenesis for Alzheimer's Disease and Frontotemporal Dementia","authors":"T. Shirasawa, Luis Carlos Aguilar Cobos","doi":"10.46459/pmu.2022006","DOIUrl":"https://doi.org/10.46459/pmu.2022006","url":null,"abstract":": Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are two major causes of dementia. These diseases are both progressive neurodegenerative diseases whereas no curative treatment has not yet been established. Regenerative approaches have been extensively researched for AD and FTD, but they are still in early phase of pre-clinical trials. We show here, for the first time, that cytokines such as hepatocyte growth factor (HGF), granulocyte colony stimulating factor (GCSF), insulin-like growth factors (IGFs), and progranulin (PGRN) can induce the neurogenesis of GABAergic and glutamatergic neurons in cerebral cortex and hippocampi of AD and FTD patients. We also showed the evidence, for the first time, that the atrophied hippocampi were significantly regenerated by cytokine-induced neurogenesis in AD and FTD patients, which was confirmed by MRI study and neurophysiological evaluations. We therefore explored the potentiality of cytokine cocktail treatment for AD and FTD and showed that cytokine-induced neurogenesis is a novel promising strategy to cure AD and FTD.","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"84 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83138645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Japanese herbal kampo medicine individually contributes to alleviating side effects of cancer patients","authors":"Y. Uezono, K. Miyano, Miki Nonaka","doi":"10.46459/pmu.2022002","DOIUrl":"https://doi.org/10.46459/pmu.2022002","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"98 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91540483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hozumi Tashima, Yuka Endo, Naoto Okada, S. Nakamura, K. Kagawa, S. Fujii, H. Miki, K. Ishizawa, M. Abe, Youichi Sato
Purpose: Cytarabine arabinoside (Ara-C) is an anti-metabolite that is commonly used as a therapeutic agent for acute leukemia; however, it can cause adverse drug reactions, such as digestive disorders, rashes, and fever. Therefore, identification of gene markers that can accurately predict the development of adverse drug reactions is useful for selecting effective drugs for therapy. After entering the cells, Ara-C is metabolized to Ara-C triphosphate, which inhibits DNA synthesis and exhibits antitumor activity. Therefore, we conducted an association study between the adverse reactions to cytarabine therapy and single nucleotide polymorphisms (SNPs) in cytarabine metabolic genes. Methods: Among the patients treated with cytarabine at the Department of Hematology at Tokushima University Hospital, 46 patients provided informed consent and were included in this study. We selected 14 tag SNPs located in nine genes that are involved in the cytarabine metabolic pathway; these SNPs were genotyped using the polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) technique. Association analyses between adverse reactions to AraC therapy and SNPs were performed using logistic regression analysis. Results: The rs9394992 polymorphism in the SLC29A1 gene and rs3886768 polymorphism in the DCTD gene were associated with the development of rash after Ara-C therapy. The rs7277 polymorphism in the DCTD gene was associated with fever, and the rs16945930 polymorphism in the ABCC11 gene was associated with sore throat. Conclusions: Our findings suggest that SNPs in the Ara-C metabolic genes influence the development of adverse reactions to Ara-C, and the results suggest that these genes can be predictive of adverse reactions to Ara-C therapy.
{"title":"Association analysis between adverse drug reactions to cytarabine therapy and single nucleotide polymorphisms in cytarabine metabolic genes in patients with hematopoietic tumor","authors":"Hozumi Tashima, Yuka Endo, Naoto Okada, S. Nakamura, K. Kagawa, S. Fujii, H. Miki, K. Ishizawa, M. Abe, Youichi Sato","doi":"10.46459/pmu.2021002","DOIUrl":"https://doi.org/10.46459/pmu.2021002","url":null,"abstract":"Purpose: Cytarabine arabinoside (Ara-C) is an anti-metabolite that is commonly used as a therapeutic agent for acute leukemia; however, it can cause adverse drug reactions, such as digestive disorders, rashes, and fever. Therefore, identification of gene markers that can accurately predict the development of adverse drug reactions is useful for selecting effective drugs for therapy. After entering the cells, Ara-C is metabolized to Ara-C triphosphate, which inhibits DNA synthesis and exhibits antitumor activity. Therefore, we conducted an association study between the adverse reactions to cytarabine therapy and single nucleotide polymorphisms (SNPs) in cytarabine metabolic genes. Methods: Among the patients treated with cytarabine at the Department of Hematology at Tokushima University Hospital, 46 patients provided informed consent and were included in this study. We selected 14 tag SNPs located in nine genes that are involved in the cytarabine metabolic pathway; these SNPs were genotyped using the polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) technique. Association analyses between adverse reactions to AraC therapy and SNPs were performed using logistic regression analysis. Results: The rs9394992 polymorphism in the SLC29A1 gene and rs3886768 polymorphism in the DCTD gene were associated with the development of rash after Ara-C therapy. The rs7277 polymorphism in the DCTD gene was associated with fever, and the rs16945930 polymorphism in the ABCC11 gene was associated with sore throat. Conclusions: Our findings suggest that SNPs in the Ara-C metabolic genes influence the development of adverse reactions to Ara-C, and the results suggest that these genes can be predictive of adverse reactions to Ara-C therapy.","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82147912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marowa Hashimoto, K. Funahashi, T. Maeda, A. Sagawa, T. Izumihara, Eisuke Shono, H. Matsuno, K. Fukuda, S. Hayashi, R. Kuroda, T. Matsubara
Purpose: Two anti-TNF biologics, infliximab and etanercept, are extremely useful for inflammatory diseases such as rheumatoid arthritis (RA). However, approximately 20 to 30% of RA have been described as non-responders. Here, we analyzed the statistical relationships of whole genome single nucleotide polymorphisms (SNPs) with remission or low disease activity (LDA) among RA and developed algorithms using SNPs to predict effectiveness of these biologics. Methods: The total study subjects (first, second and validation population for each infliximab and etanercept) were 260 RA patients for infliximab and another 251 RA patients for etanercept. Effectiveness of infliximab and etanercept was assessed using DAS28-CRP. In first, second and the combined population, relationships of 277,339 SNPs with remission and LDA were analyzed using case-control analyses by Fisher’s exact tests for each infliximab and etanercept. We picked up SNPs (P < 0.05) from each first, second and combined population. Then, 10 SNPs with lower P value in the combined population were selected from common SNPs among the first, second and combined populations. We developed algorithms using the 10 SNPs to predict effectiveness of infliximab and etanercept. In the validation population, availability of the algorithms was evaluated. Results: Using combined infliximab-remission and LDA algorithms in the validation population, the accuracy was 90.4%. Using combined etanercept-remission and LDA algorithms in validation population, the accuracy was 76.8%. Conclusions: The combined use of our two algorithms using SNPs may be very useful in the prediction of remission or LDA before treatment with infliximab or etanercept.
{"title":"Algorithms using genome-wide association studies for prediction of effectiveness of biologics in rheumatoid arthritis","authors":"Marowa Hashimoto, K. Funahashi, T. Maeda, A. Sagawa, T. Izumihara, Eisuke Shono, H. Matsuno, K. Fukuda, S. Hayashi, R. Kuroda, T. Matsubara","doi":"10.46459/pmu.2019019","DOIUrl":"https://doi.org/10.46459/pmu.2019019","url":null,"abstract":"Purpose: Two anti-TNF biologics, infliximab and etanercept, are extremely useful for inflammatory diseases such as rheumatoid arthritis (RA). However, approximately 20 to 30% of RA have been described as non-responders. Here, we analyzed the statistical relationships of whole genome single nucleotide polymorphisms (SNPs) with remission or low disease activity (LDA) among RA and developed algorithms using SNPs to predict effectiveness of these biologics. Methods: The total study subjects (first, second and validation population for each infliximab and etanercept) were 260 RA patients for infliximab and another 251 RA patients for etanercept. Effectiveness of infliximab and etanercept was assessed using DAS28-CRP. In first, second and the combined population, relationships of 277,339 SNPs with remission and LDA were analyzed using case-control analyses by Fisher’s exact tests for each infliximab and etanercept. We picked up SNPs (P < 0.05) from each first, second and combined population. Then, 10 SNPs with lower P value in the combined population were selected from common SNPs among the first, second and combined populations. We developed algorithms using the 10 SNPs to predict effectiveness of infliximab and etanercept. In the validation population, availability of the algorithms was evaluated. Results: Using combined infliximab-remission and LDA algorithms in the validation population, the accuracy was 90.4%. Using combined etanercept-remission and LDA algorithms in validation population, the accuracy was 76.8%. Conclusions: The combined use of our two algorithms using SNPs may be very useful in the prediction of remission or LDA before treatment with infliximab or etanercept.","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85593086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
: Immune resilience is the ability for the human body to adapt and respond to adverse conditions, such as bacterial patho-gens, viral infections, and abnormal or cancerous cells. Our ability to mount an appropriate response against such illness re-lates directly to our level of immune resilience, which in turn is impacted by our lifestyle choices. Nutrition, exercise, sleep and stress management are powerful influencers of mucosal immunity, the first line of defense against pathogens, and the exposome, exogenous and endogenous factors affecting our overall health. Lifestyle medicine offers evidence-based recommendations on how to optimize our immune system to withstand and thwart infections and disease.
{"title":"Immune resilience in the age of COVID-19 and beyond– A Lifestyle Medicine approach","authors":"Minako Abe, H. Abe","doi":"10.46459/pmu.2020012","DOIUrl":"https://doi.org/10.46459/pmu.2020012","url":null,"abstract":": Immune resilience is the ability for the human body to adapt and respond to adverse conditions, such as bacterial patho-gens, viral infections, and abnormal or cancerous cells. Our ability to mount an appropriate response against such illness re-lates directly to our level of immune resilience, which in turn is impacted by our lifestyle choices. Nutrition, exercise, sleep and stress management are powerful influencers of mucosal immunity, the first line of defense against pathogens, and the exposome, exogenous and endogenous factors affecting our overall health. Lifestyle medicine offers evidence-based recommendations on how to optimize our immune system to withstand and thwart infections and disease.","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87390464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
: Purpose: Rhythm exercise, such as walking, is effective in reducing stress associated with mental disorders, including anxiety and depression. Belt electrode skeletal muscle electrical stimulation (B-SES) can promote muscle contraction at a constant rhythm throughout the lower limbs without voluntary effort. B-SES may serve as a therapeutic strategy similar to rhythm exercise. The purpose of this study was to measure the effect of B-SES on stress on the basis of salivary amylase levels, a highly reliable stress index. Methods: This study was a randomized controlled trial in which 30 healthy men were randomly assigned to three stimulation condition groups (DISUSE B-SES group, METABO B-SES group, and Control group). The salivary amylase levels were measured before, immediately after, and 30 minutes after the intervention. Changes in the salivary amylase levels were analyzed using repeated-measures analysis of variance. Results: The METABO B-SES group had significantly different outcomes immediately after the intervention and 30 minutes after the end of the intervention. Conclusion: METABO B-SES may contribute to stress reduction.
{"title":"Effect of belt electrode skeletal muscle electrical stimulation on psychological stress","authors":"Kouki Tomida, H. Nakae","doi":"10.46459/pmu.2019020","DOIUrl":"https://doi.org/10.46459/pmu.2019020","url":null,"abstract":": Purpose: Rhythm exercise, such as walking, is effective in reducing stress associated with mental disorders, including anxiety and depression. Belt electrode skeletal muscle electrical stimulation (B-SES) can promote muscle contraction at a constant rhythm throughout the lower limbs without voluntary effort. B-SES may serve as a therapeutic strategy similar to rhythm exercise. The purpose of this study was to measure the effect of B-SES on stress on the basis of salivary amylase levels, a highly reliable stress index. Methods: This study was a randomized controlled trial in which 30 healthy men were randomly assigned to three stimulation condition groups (DISUSE B-SES group, METABO B-SES group, and Control group). The salivary amylase levels were measured before, immediately after, and 30 minutes after the intervention. Changes in the salivary amylase levels were analyzed using repeated-measures analysis of variance. Results: The METABO B-SES group had significantly different outcomes immediately after the intervention and 30 minutes after the end of the intervention. Conclusion: METABO B-SES may contribute to stress reduction.","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74450800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：